Pegfilgrastim Market Report 2025 (Global Edition)

Global Pegfilgrastim Market Report 2024 Market Size Split by Type (Powder, Reagent, Other), by Application (Oncology, Hematological DIsease, Other), by Distribution Channel (Online, Offline)

Pegfilgrastim Market Report Description

We have various report editions of Pegfilgrastim Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Pegfilgrastim Market

The competitive landscape of the Pegfilgrastim market is characterized by a diverse range of players competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. Key players in the market include established electronics manufacturers, specialized Pegfilgrastim companies, and emerging start-ups aiming to disrupt the market with innovative solutions.

February 2022: Biocon Biologics Ltd., a fully integrated biopharmaceutical company based in India, acquired Viatris' biosimilar business for $3.34 billion. This acquisition enables Biocon Biologics to direct-market its existing and upcoming biosimilars more effectively. To ensure seamless customer service and a smooth transition, Viatris is expected to provide commercial and other transition services for a projected two-year period. Viatris Inc., a US-based pharmaceutical and healthcare corporation, has co-developed a biosimilar of pegfilgrastim. (Source:https://www.biocon.com/biocon-biologics-to-acquire-viatris-global-biosimilars-assets-in-transformational-deal/ ) January 2021: According to The American Cancer Society, a US-based cancer-fighting organization, the number of new cancer cases in the USA increased from 1.8 million in 2020 to 1.9 million in 2021. Additionally, cancer-related deaths rose slightly from 606,520 in 2020 to 608,570 in 2021. (Source:https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html )

Top Companies Market Share in Pegfilgrastim Industry: (In no particular order of Rank)

• Coherus Biosciences
• Mylan N.V.
• Biocon
• Novartis AG (Sandoz)
• Pfizer Inc.
• Green Cross Corp
• Accord healthcare
• Intas Pharmaceuticals Ltd.
• Zydus Cadila
• Mundipharma
• Fresenius Kabi
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Pegfilgrastim Market

Which Region Dominates the Pegfilgrastim Market in 2024?

According to Cognitive Market Research, North America dominated the pegfilgrastim market in 2024, accounting for around 40% of the global revenue. This dominance is attributed to factors such as the high prevalence of cancer, advanced healthcare infrastructure, significant healthcare spending, and the presence of major pharmaceutical companies in the region. Additionally, increased awareness and adoption of biosimilars have contributed to the market's growth in North America.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the pegfilgrastim market due to several key factors. Firstly, the region is experiencing a rising incidence of cancer, which increases the demand for supportive therapies like pegfilgrastim. Secondly, improving healthcare infrastructure and access to healthcare services are driving greater diagnosis rates and treatment options, further boosting the market. Thirdly, increasing healthcare expenditure and investments in oncology care contribute to the expansion of the market in Asia Pacific. Moreover, the growing awareness among healthcare professionals and patients about the benefits of pegfilgrastim in managing chemotherapy-induced neutropenia is fostering market growth in the region.

The current report Scope analyzes Pegfilgrastim Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Pegfilgrastim

According to Cognitive Market Research, the global Pegfilgrastim market size was estimated at USD 1654.2 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 661.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2031.

• According to Cognitive Market Research, the U.S. held a major share in the pegfilgrastim market with a market size of USD 522.02 million in 2024 and is projected to grow at a CAGR of 9.5% during the forecast period. The increasing incidence of cancer, advanced healthcare infrastructure, high healthcare expenditure, and significant investment in cancer treatment and supportive care amplify the demand. Additionally, the strong presence of major pharmaceutical companies and the growing adoption of biosimilars contribute to this robust market growth.
• The Canada pegfilgrastim market had a market share of USD 79.40 million in 2024 and is projected to grow at a CAGR of 10.5% during the forecast period. An increasing cancer incidence rate, enhanced healthcare infrastructure, and rising government investments in cancer care and supportive therapies drive this growth. Additionally, the growing awareness and adoption of biosimilars are further contributing to the market's expansion in Canada.
• The Mexico Pegfilgrastim market is projected to witness growth at a CAGR of 10.2% during the forecast period, with a market size of USD 60.21 million in 2024.

Europe Pegfilgrastim

According to Cognitive Market Research, the global Pegfilgrastim market size was estimated at USD 1654.2 Million, out of which Europe held the market more than 30% of the global revenue with a market size of USD 496.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031. 024 and is projected to grow at a CAGR of 10.8% during the forecast period. In the U.K., pegfilgrastim sales witness an upswing due to the rising incidence of cancer, strong healthcare infrastructure, and significant government funding for cancer treatment and supportive care. Additionally, increased awareness of pegfilgrastim's benefits in managing chemotherapy-induced neutropenia and the growing adoption of biosimilars contribute to the market's growth.

The France Pegfilgrastim market is projected to witness growth at a CAGR of 9.2% during the forecast period, with a market size of USD 45.66 million in 2024.

According to Cognitive Market Research, the Germany Pegfilgrastim market size was valued at USD 98.26 million in 2024 and is projected to grow at a CAGR of 10.2% during the forecast period.

The Italy Pegfilgrastim market is projected to witness growth at a CAGR of 9.4% during the forecast period, with a market size of USD 42.88 million in 2024.

The Russia Pegfilgrastim market is projected to witness growth at a CAGR of 9.0% during the forecast period, with a market size of USD 76.92 million in 2024.

The Spain Pegfilgrastim market is projected to witness growth at a CAGR of 9.1% during the forecast period with a market size of USD 40.69 million in 2024

The Luxembourg Pegfilgrastim market is projected to witness growth at a CAGR of 10.1% during the forecast period, with a market size of USD 15.38 million in 2024.

The Portugal Pegfilgrastim market is projected to witness growth at a CAGR of 9.8% during the forecast period, with a market size of USD 10.42 million in 2024.

The Greece Pegfilgrastim market is projected to witness growth at a CAGR of 10.3% during the forecast period, with a market size of USD 5.96 million in 2024.

Rest of Europe's Pegfilgrastim market is projected to witness growth at a CAGR of 8.7% during the forecast period, with a market size of USD 76.92 million in 2024.

Asia Pacific Pegfilgrastim

According to Cognitive Market Research, the global pegfilgrastim market size was estimated at USD 1654.2 million, with Asia Pacific holding around 23% of the global revenue, amounting to a market size of USD 380.47 million in 2024. The market in Asia Pacific is projected to grow at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2031.

• According to Cognitive Market Research, the China Pegfilgrastim market size was valued at USD 171.21 million in 2024 and is projected to grow at a CAGR of 13.0% during the forecast period. Pegfilgrastim sales surged in China due to the increasing incidence of cancer, expanding healthcare infrastructure, rising healthcare investments, and the government's focus on improving access to advanced cancer therapies.
• The Japan Pegfilgrastim market is projected to witness growth at a CAGR of 12.0% during the forecast period, with a market size of USD 52.50 million in 2024.
• The India Pegfilgrastim market had a market share of USD 45.66 million in 2024 and is projected to grow at a CAGR of 15.3% during the forecast period.
• The South Korea Pegfilgrastim market is projected to witness growth at a CAGR of 12.6% during the forecast period, with a market size of USD 38.05 million in 2024.
• The Australia Pegfilgrastim market is projected to witness growth at a CAGR of 13.2% during the forecast period, with a market size of USD 19.78 million in 2024.
• The Southeast Asia Pegfilgrastim market is projected to witness growth at a CAGR of 14.5% during the forecast period, with a market size of USD 26.25 million in 2024.
• The Rest of Asia Pacific Pegfilgrastim market is projected to witness growth at a CAGR of 13.3% during the forecast period, with a market size of USD 27.01 million in 2024.

South America Pegfilgrastim

According to Cognitive Market Research, the global Pegfilgrastim market size was estimated at USD 1654.2 Million, out of which Latin America market of more than 5% of the global revenue with a market size of USD 82.7 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.9% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Pegfilgrastim market size was valued at USD 35.40 million in 2024 and is projected to grow at a CAGR of 11.5% during the forecast period. Brazil is experiencing an increasing incidence of cancer, driving the demand for supportive therapies like pegfilgrastim to manage chemotherapy-induced side effects such as neutropenia.
• Argentina Pegfilgrastim market had a market share of USD 13.90 million in 2024 and is projected to grow at a CAGR of 11.8% during the forecast period
• Colombia Pegfilgrastim market is projected to witness growth at a CAGR of 10.7% during the forecast period, with a market size of USD 7.36 million in 2024.
• Peru Pegfilgrastim market is projected to witness growth at a CAGR of 11.1% during the forecast period, with a market size of USD 6.78 million in 2024.
• Chile Pegfilgrastim market is projected to witness growth at a CAGR of 11.2% during the forecast period, with a market size of USD 5.96 million in 2024.
• The Rest of Latin America Pegfilgrastim market is projected to witness growth at a CAGR of 10.0% during the forecast period, with a market size of USD 13.32 million in 2024.

Middle East and Africa Pegfilgrastim

According to Cognitive Market Research, the global Pegfilgrastim market size was estimated at USD 1654.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 33.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.2% from 2024 to 2031.

According to Cognitive Market Research, the global Pegfilgrastim market size was estimated at USD 1654.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 33.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.2% from 2024 to 2031.

Pegfilgrastim Market Analysis

Pegfilgrastim Market Type Segment Analysis

According to Cognitive Market Research, Among the segments of the pegfilgrastim market, the dominating segment is the Powder type. Powder formulations are preferred for their stability, ease of storage, and efficient reconstitution properties, making them convenient for healthcare providers and patients alike. The powder form allows for precise dosing and longer shelf life compared to liquid formulations, thereby enhancing its adoption in clinical settings. These advantages contribute to the powder segment's significant market share and continued dominance in the pegfilgrastim market.

The fastest-growing segment in the pegfilgrastim market is the Reagent type. Reagents play a crucial role in laboratory diagnostics and research applications, driving their increasing demand in healthcare settings. As the emphasis on personalized medicine and diagnostic accuracy grows, so does the demand for high-quality reagents used in the preparation and analysis of pegfilgrastim and related biologics. This trend is bolstered by advancements in biotechnology and increasing research investments, positioning the reagent segment for rapid expansion within the pegfilgrastim market.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Pegfilgrastim Industry. Request a Free Sample PDF!

According to Cognitive Market Research, In the pegfilgrastim market, oncology emerges as the dominating segment. Oncology applications constitute the largest share due to the widespread use of pegfilgrastim in managing chemotherapy-induced neutropenia in cancer patients. With the increasing incidence of various types of cancer globally, including breast, lung, and colorectal cancers, the demand for pegfilgrastim continues to grow robustly within the oncology segment. This trend is supported by advancements in cancer treatments and a growing emphasis on supportive care to enhance patient outcomes and quality of life during chemotherapy.

The fastest-growing segment in the pegfilgrastim market is hematology. The segment is witnessing rapid growth due to rising awareness and diagnosis rates of hematological diseases such as leukemia, lymphoma, and myeloma. Pegfilgrastim plays a crucial role in managing neutropenia associated with treatments for these diseases, thereby driving its adoption in hematology. Additionally, advancements in treatments for hematological disorders, coupled with increasing healthcare investments in this specialized area, further propel the growth of pegfilgrastim usage within the hematology segment.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Pegfilgrastim Distribution Channel Segment Analysis

According to Cognitive Market Research, the offline distribution channel currently dominates the pegfilgrastim market. This segment includes hospitals, clinics, and retail pharmacies where healthcare professionals directly prescribe and dispense pegfilgrastim to patients undergoing chemotherapy. Offline channels offer face-to-face interactions with healthcare providers, ensuring personalized care and immediate access to medications. Moreover, the established infrastructure and regulatory compliance of offline channels inspire confidence among patients regarding product authenticity and safety, contributing to its dominance in the current market landscape.

The online distribution channel is emerging as the fastest-growing segment in the pegfilgrastim market. This growth is fueled by increasing digitalization in healthcare, convenience in purchasing medications from home, and broader internet penetration. Online platforms offer patients and caregivers easier access to information about pegfilgrastim, competitive pricing, and home delivery options, which are particularly advantageous for chronic disease management like chemotherapy support. The trend towards online pharmacies and e-commerce platforms in healthcare is expected to accelerate further, making online distribution a key growth driver in the pegfilgrastim market.

• Online
• Offline

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion